List view / Grid view
Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD, Chief Scientific Officer at CoRegen and Associate Professor at Baylor University, to uncover the mechanisms of SRC-3 and why it’s key to targeting cancer – and only cancer.
Organoids, lab-grown 3D structures that mimic human organs, are redefining preclinical research through bypassing the ethical and practical limitations of animal models. Technological advancements in organoid research, including automation and improved analytical tools, promise to unlock new possibilities by streamlining the application of these 3D structures to enhance drug development…
New research has uncovered a hitherto unknown mechanism whereby chemokines form DNA-bound nanoparticles that play a key role in autoimmune disorders.
Scientists in Japan have developed a credible heart cell model for arrhythmogenic cardiomyopathy and observed a positive response in the condition using PKP2 gene therapy.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.
A research team based at Skoltech in Russia has developed an artificial intelligence-driven solution for highly accurate detection of efficacious binding sites to expedite drug discovery.
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
A new protein can trick SARS-CoV-2 and bind to the Spike protein rather than cell membranes in a kidney organoid.
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.